


Brilliant Violet 711™ anti-mouse CD31**Catalog # / Size:** 1112245 / 50 µg**Clone:** 390**Isotype:** Rat IgG2a, κ**Immunogen:** C3H/HeJ mouse hematopoietic progenitor cell line 3**Reactivity:** Mouse**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)**Concentration:** 0.2 mg/mL

C57BL/6 mouse splenocytes were stained with CD31 (clone 390) Brilliant Violet 711™ (filled histogram) or rat IgG2a, κ Brilliant Violet 711™ isotype control (open histogram).

Applications:**Applications:** Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.125 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Anti-mouse CD31 clones 390 and MEC13.3 bind to their respective non-overlapping epitopes in IgD2 of CD31.⁸ Additional reported applications (for the relevant formats) include: immunoprecipitation¹, *in vitro* and *in vivo* blocking of CD31-mediated cell-cell interactions¹⁻⁴, and immunohistochemical staining^{5,6,7} of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections. **Special Note:** This antibody is not recommended for formalin-fixed paraffin-embedded sections.

**Application
References:**

1. Baldwin HS, *et al.* 1994. *Development* 120:2539. (IP, Block)
 2. DeLisser HM, *et al.* 1997. *Am. J. Pathol.* 151:671. (Block)
 3. Rosenblum WI, *et al.* 1996. *Stroke* 27:709. (Block)
 4. Iguchi A, *et al.* 1997. *Cell Struct. Funct.* 22:357. (Block)
 5. Wyder L, *et al.* 2000. *Cancer Res.* 60:4682. (IHC)
 6. Wiewrodt R, *et al.* 2002. *Blood* 99:912. (IHC)
 7. McQualter JL, *et al.* 2009. *Stem Cells.* 27:623. (IHC) [PubMed](#)
 8. Chacko AM, *et al.* 2012. *PLoS One* 7:e34958.
 9. Greineder CF, *et al.* 2013. *PLoS One.* 14:80110. [PubMed](#)
-

Description:

CD31 is a 130-140 kD glycoprotein, also known as platelet endothelial cell adhesion molecule (PECAM-1) and EndoCAM. It is a member of the Ig superfamily, expressed on endothelial cells, platelets, granulocytes, monocytes/macrophages, dendritic cells, and T and B cell subsets, and is critical for cell-cell interactions. The primary ligands for CD31 have been reported to be CD38 and the vitronectin receptor ($\alpha_v \beta_3$ integrin, CD51/CD61). Other reported functions of CD31 are neutrophil emigration to sites of inflammation and angiogenesis.

**Antigen
References:**

1. Barclay AN, *et al.* 1997. *The Leukocyte Antigen FactsBook* Academic Press.
2. DeLisser HM, *et al.* 1994. *Immunol. Today* 15:490.
3. Newman PJ, *et al.* 1990. *Science* 247:1219.